Neuroendocrine Tumors: Beta Labeled Radiopeptides

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceutical Therapy

Background:

• Peptide receptor radionuclide therapy (PRRT) targets somatostatin receptors on neuroendocrine tumor cells using radiolabeled octreotide derivatives.
• While initially using 90Y-peptides, 177Lu-peptides are now the standard for PRRT.
• PRRT achieves significant tumor and symptomatic control, but responses are often transient.

Purpose of the Study:

• To review current strategies for enhancing PRRT efficacy and tolerability.
• To highlight the importance of personalized treatment approaches in PRRT.
• To emphasize the role of dosimetry and radiosensitivity assessment.

Main Methods:

• Administration of radiolabeled octreotide derivatives targeting somatostatin receptors.
• Utilization of 177Lu-labeled peptides as the predominant therapeutic agent.
• Focus on individualized treatment planning based on dosimetric estimates.

Main Results:

• PRRT demonstrates substantial tumor and symptomatic control in neuroendocrine tumor patients.
• Current therapeutic responses are limited in duration.
• Ongoing research into novel peptides and strategies aims to improve outcomes.

Conclusions:

• Personalized PRRT, guided by precise dosimetry for tumors and normal organs, is crucial.
• Assessing tissue radiosensitivity is a critical factor for optimizing treatment.
• Further advancements in peptide design and therapeutic strategies are needed to improve long-term efficacy and tolerability.